Abstract Body

Background: A simple blood test for active TB disease remains a critical unmet need worldwide. Most serodiagnostic assays to date have been based on a single or small number of antigens and have not provided adequate diagnostic accuracy. A hypothesis is that a multiplexed panel of antigen-antibody interactions could provide a signature indicative of active disease. FIND has led a comprehensive TB proteome effort and identified a set of 57 potentially discriminatory antigens. To further down-select to a diagnostic antigen set, it was determined that testing fresh specimens in endemic countries was critical. The portable MBio multiplexed array platform was selected as uniquely suited for this task and a multi-phase clinical research program was initiated. This abstract presents results from the first phase, designed to establish the operational functionality of the MBio system.

Methodology: Disposable assay cartridges incorporating 57 TB proteins and 31 assay controls in a microarray were developed. Cartridges processed with 10 microliters of diluted whole blood or 5 microliters of diluted serum are analyzed on the MBio reader for fluorescence detection of individual antigenantibody reactivities. A representative image is provided below. To establish performance of the MBio platform, 200 TB suspects were enrolled and tested on systems installed at trial sites in Peru and Vietnam. Endpoints included concordance between the MBio field platforms and a Luminex laboratory reference, indeterminate rate, reliability, and ease of use.

Results: All operational endpoints were met. To compare MBio and Luminex, directional concordance around the mean fluorescence intensity for each antigen was assessed for the collection of frozen serum samples. All antigens showed directional concordance of >75% for all samples, with the majority showing > 90% concordance. The indeterminate rate was 7.4% initially, and after an adjustment of the analysis algorithm, the indeterminate rate decreased to 0.77%. There were zero instrument or software failures over the 673 cartridges tested and user errors were observed in only 2 of 673 cartridges tested.

Conclusions: The MBio system was shown to be a reliable platform for rapidly detecting a large panel of antigen-antibody interactions from whole blood or serum in TB-endemic settings. As a result of this phase I success, the study was advanced to a larger clinical evaluation to investigate diagnostic utility of the array.